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Introduction: The primary objective of this sub analysis of the CONOCES study was to analyse outcomes in terms
of mortality rates, quality of life and degree of autonomy over the first year in patients admitted to stroke units in
Spain. The secondary objective was to identify the factors determining good prognosis.
Methods: We studied a sample of patients who had suffered a confirmed stroke and been admitted to a Stroke
Unit in the Spanish healthcare system. Socio-demographic and clinical variables and variables related to the level of
severity (NIHSS), the level of autonomy (Barthel, modified Rankin) and quality of life (EQ-5D) were recorded at the
time of admission and then three months and one year after the event. Factors determining prognosis were
analysed using logistic regression and ROC curves.
Results: A total of 321 patients were recruited, 33% of whom received thrombolytic treatment, which was
associated with better results on the Barthel and the modified Rankin scales and in terms of the risk of death. Mean
quality of life measured through EQ-5D improved from 0.57 at discharge to 0.65 one year later. Full autonomy level
measured by Barthel index increased from 30.1% at discharge to 52.8% at one year and by the modified Rankin
scale from 51% to 71%. The rates for in-hospital and 1-year mortality were 5.9% and 17.4% respectively. Low NIHSS
scores were associated with a good prognosis with all the outcome variables. The three instruments applied (NIHSS,
Barthel and modified Rankin scales) on admission showed good discriminative ability for patient prognosis in the
ROC curves.
Conclusions: There has been a change in the prognosis for stroke in Spain in recent years as the quality of life at
1 year observed in our study is clearly higher than that obtained in other Spanish studies conducted previously.
Moreover, survival and functional outcome have also improved following the introduction of a new model of care.
These results clearly promote extension of the model based on stroke units and reinforced rehabilitation to the
majority of the more than 100,000 strokes that occur annually in Spain.
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In the 20th century, specific treatment for stroke was
mainly directed at primary prevention, with a particular
focus on controlling risk factors like hypertension [1-3].
While patients were in hospital, the clinician’s role was lim-
ited to maintaining vital functions and preventing compli-
cations [4]. The advent of thrombolysis and its successful
use in acute myocardial infarction opened the way for an
active approach to patient care, which led to the creation
of stroke units [5-7]. At the same time the Stroke National
Plan reinforced the key role of rehabilitation in the final
outcome [8,9]. With this change in the model of care, it
was recognised that the care received during hospitalisa-
tion and in the first year is a critical element in the progno-
sis of patients with stroke, both in terms of survival and
functional status, and thus a determining factor in the
resulting economic and social burden [7]. The new pro-
active approach enabled the previous fatalistic attitude to
be overcome and led to improved outcomes through the
incorporation of evidence-based therapies such as reperfu-
sion and stroke units into the standard treatment [1,7-10].
Thus, the healthcare system placed emphasis on the char-
acteristics of the different care levels with promotion of ref-
erence stroke hospitals, set up less restrictive stroke code
activation criteria that included new therapeutic options,
established new standard measures for endovascular treat-
ment, reinforced the rehabilitation process and developed
tele-medicine stroke networks [8,9].
Current demographic trends towards aging mean that
measurement of the burden of disease has had to give
greater priority to diseases which, in addition to causing
mortality, also generate disability [11,12]. As a result,
health-related quality of life (HRQOL) has become a key
element when measuring outcomes of medical interven-
tions [13,14]. However, most of the studies carried out
in Spain on the impact of stroke on HRQOL are dated
from several years ago [15-17]. It is therefore necessary
to measure the impact that the widespread introduction
of stroke units has had on patients’ HRQOL and level of
autonomy, in order to assess the improvements made to
secondary and tertiary stroke prevention [18].
The primary objective of this part of the CONOCES
study [19] was to analyse outcomes in terms of mortality
rates, health-related quality of life (HRQOL) and degree
of autonomy in patients admitted to stroke units in
Spain over the first year after admission. The secondary
objective was to identify the factors determining good
outcome.
Methods
Type of study and design
CONOCES was a prospective, observational, epidemio-
logical, naturalistic, multicentre study of costs and out-
comes of the disease in the Spanish healthcare setting in asample of patients who had suffered a confirmed stroke
[19]. The inclusion criteria were: being over 18 years of
age; confirmed clinical diagnosis of first ischaemic or
haemorrhagic stroke within 24 hours of onset; admission
to a stroke unit; voluntary participation in the study; and
signed informed consent by the patient and/or their pri-
mary caregiver. During the recruitment phase patients who
met the inclusion criteria were enrolled consecutively in
the study in all the participant centres. The study variables
were collected by the medical team through personal inter-
views with the patient and the primary caregiver during
the hospital stay in the stroke units and at the follow-up
visits at 3 and 12 months. In the first data collection all the
autonomy and quality of life scales were recorded at hos-
pital discharge. Only the mRS was also recorded at admis-
sion. The protocol was approved by the Ethics Committee
of Hospital Clínic i Provincial de Barcelona.
The variables were socio-demographic (age, gender
and residence) and clinical (activation of stroke proto-
col, time to neurological care, aetiology, recurrence,
presence of atrial fibrillation (AF), thrombolytic therapy
and death during the follow-up period) in nature.
HRQOL and degree of autonomy, as well as their deter-
mining factors, were also measured by determining
neurological status on admission using the National In-
stitutes of Health Stroke Scale (NIHSS) [20] and by
assessing the patients’ disability by measuring func-
tional status with the Barthel Index (BI) [21] and degree
of functional dependence with the modified Rankin
Scale (mRS) at discharge, three months and one year
[22]. BI and mRS are the most commonly used meas-
urement scales to assess the level of autonomy of stroke
patients. mRS has become the most widely used clinical
outcome measure for stroke in clinical trials. The scale
ranks from 0 to 6, from perfect health with no symp-
toms to death [22]. Although the mRS classifies deaths
in category 6, we decided to exclude them from the
functional status analyses. BI is an ordinal scale used to
measure performance in daily living activities. Each per-
formance item is rated on this scale with a given num-
ber of points assigned to each level or ranking. It uses
ten variables to describe mobility, feeding, toilet use,
dressing, bathing, faecal and urinary incontinence, help
needed with grooming and other activities. A higher
number is associated with a greater likelihood of being
able to live at home with a degree of independence fol-
lowing discharge from hospital. Each item can score 0, 5
or 10 points, so that BI score range from 0 to 100, cor-
responding to five levels of dependence: independent
(100 points), low dependence (91–99 points), moderate
dependence (61–90 points), severe dependence (21–60
points), total dependence (0–20) [21,23]. NIHSS has be-
come the most widely-used scale to assess initial neuro-
logical status, in the follow-up of patients on treatment
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[24,25]. It is composed of 11 items, each of which scores
a specific ability between 0 and 4. For each item, a score
of 0 typically indicates normal function in that specific
ability, while a higher score is indicative of some level of
impairment. The individual scores from each item are
summed in order to calculate a patient’s total NIHSS
score. The maximum possible score is 42, with the
minimum score being 0 [24,25].
HRQOL was measured using the generic questionnaire
EuroQuol (EQ-5D) at the same three time points [26].
The EQ-5D questionnaire was completed by the patients
at the scheduled follow-up visits for the study. EQ-5D is
a standardised instrument to measure self-reported
health status with respect to five dimensions (mobility,
self-care, usual activities, pain/discomfort, anxiety/de-
pression) and three levels of severity (no problems, some
or moderate problems, and extreme problems). It is
characterised by the fact that it provides a single index
value for each health state which can have a value of 1
or less, where 1 is equivalent to full health and 0 is
death. These were normalised using conversion tables
obtained in the general Spanish population [27]. When
the patient was unable to communicate, the interviewer
conducted the test to a close relative or caregiver [28].
Statistical analysis
Statistical differences in the comparison of contingency
tables were analysed using the chi-square test, taking a
value of α equal to or less than 0.05. Given that the vari-
ables are not normally distributed, the Wilcoxon test
was used to measure the statistical significance of differ-
ences between means, as with ordinal data. All statistical
analyses were carried out using SPSS software (version
21; SPSS Inc., Chicago, IL).
To analyse the magnitude of the observed change in
the quality of life, the value of the final EQ-5D was com-
pared with the original and with a sample of general
population over 65 using the effect size [29]. The EQ-5D
sample used to describe general population characteris-
tics proceeded from a random sample of general popula-
tion from the Canary Islands [30] which mean score was
0.73 and standard deviation 0.32. Cohen defined as non-
significant an effect size of less than 0.2, an effect size
between 0.2 and 0.5 as small, between 0.5 and 0.8 as
moderate, and greater than 0.8 as large [29].
To analyse the association of clinical variables on ad-
mission with functional capacity and HRQOL after a
year, statistical logistic regression analyses were per-
formed in which the dependent variables were mortality,
the value 1 in EQ-5D, modified Rankin Scale level 0–2,
Barthel below 61 (total or severe dependence) and
Barthel 100. The independent variables were age, gender,
arrival time to neurological care, aetiology (ischaemic orhaemorrhagic), AF, NIHSS, hospital arrival time and
thrombolytic therapy (yes/no). The likelihood of receiv-
ing thrombolytic therapy was further investigated in a
logistic regression model in which the explanatory vari-
ables were age, gender, NIHSS and the time of arrival.
Furthermore, we used an approach based on the ana-
lysis of ROC (Receiver Operating Characteristic) curves
to measure sensitivity to change. This allowed us to as-
sess the ability of the instruments used on admission,
such as the NIHSS, the mRS and the BI, to detect pa-
tients with good prognosis, using the same methodology
that is used to determine whether or not a diagnostic
test identifies the condition of interest [31]. The ROC
curve is obtained by plotting sensitivity for each break-
point on the y-axis and its corresponding 1-specificity
on the x-axis. If the instrument is sensitive, it has an
ROC curve where sensitivity peaks have associated mini-
mum values of 1-specificity. Conversely, if the instru-
ment is insensitive, it has an ROC curve near to the
reference line (line dividing the axis into two equal parts,
which indicates the minimum level of discrimination).
To characterise the instrument as discriminant, areas
greater than 70% are required. The statistical method
also calculated the statistical significance of the curve.
Results
A total of 321 patients were enrolled in the study be-
tween November 2010 and May 2011. Eight patients
were lost to follow-up between discharge and the 3-
month visit, and a further 7 by 12 months. The mean
age was 72.1 years (SD 13.2) and 176 patients (54.8%)
were male. The main socio-demographic and clinical
characteristics of the sample are shown in Table 1. We
should highlight that 33% of patients received thrombo-
lytic therapy. The rates for in-hospital and 1-year mor-
tality were 5.9% and 17.4% respectively.
The level of autonomy and quality of life from admission
to one year later improved on all scales (Table 2). The per-
centage of category 3 (no problems) in the dimensions of
the EQ-5D increased across the board. Figure 1 shows how
functional level evolved according to the BI from admission
to 12 months. The effect size for EQ-5D obtained from
hospital discharge to 12 months was small (0.25). When we
compared the EQ-5D values of general population with the
mean value at 12 months the same effect size was attained.
However the Visual Analogic Scale scores did not show
any statistically significant differences between the admis-
sion and after one year.
In the univariate analysis (Table 3), age, NIHSS on ad-
mission and the presence of AF appear as variables sta-
tistically associated with level of autonomy (Barthel and
modified Rankin scores at 1 year). In contrast, aetiology,
thrombolysis and time of arrival are not statistically sig-
nificant. Male gender is statistically associated with a
Table 1 Socio-demographic and clinical characteristics of
the patients




Living Environment Value %
Home 316 98.4
Residential Care for the Elderly 3 0.9
Other 2 0.6
Stroke Protocol Activated Value %
No 147 45.8
Yes 167 52
Time to neurological care Frequency Percentage
0-1.5 hours 71 22.7
1.5-3 hours 94 30
3-4.5 hours 34 10.9
>4.5 hours 114 36.4
Type of stroke Value %
Cerebral Infarction 291 90.7
Haemorrhage 30 9.3
Stroke recurrence at 1 year Value %
Yes 25 7.8
No 296 92.2
Atrial Fibrillation Value %
Yes 161 50.2
No 160 49.8
Thrombolysis total Value %
Yes 106 33.0
No 215 67.0
Thrombolysis NIHSS 6-42 Value %
Yes 92 50.8
No 89 49.2
Thrombolysis NIHSS 0-5 Value %
Yes 14 10.0
No 126 90.0
Death while in hospital Value %
Yes 19 5.9
No 302 94.1
Death during the year of study Value %
Yes 56 17.4
No 265 82.6
NIHSS on admission Value %
Minor strokes (1–3) 86 26.8
Moderate strokes (4–10) 114 35.5
Severe strokes (>10) 121 37.7
NIHSS: National Institute of Health Stroke Scale.
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kin between 0 and 2.
The results of logistic regression analysis are presented in
Table 4 and show that low NIHSS is associated with good
prognosis for all outcome variables. Being under the age of
75 was only associated with a better outcome for mortality
and low modified Rankin score. Males had better quality of
life and increased autonomy in terms of Barthel 100. Al-
though in the univariate analysis the prognosis in patients
treated with thrombolysis was found to be no different
(Table 3), in the logistic regression, this treatment appears
to be associated with better outcome for the Barthel and
modified Rankin scores and the risk of death (Table 4). The
reason for this difference is the distribution of patients ac-
cording to NIHSS and thrombolysis, as half of the patients
who were in the 6–42 group of the NIHSS received
thrombolytic therapy while only 10% of those in the 0–5
group did so (Table 1).
The explanatory logistic regression of the probability
of thrombolysis showed statistically significant values for
a mild NIHSS (OR 8.3) and time of arrival less than
3 hours (OR 9.5). No statistically significant associations
were found with age or gender. The ROC curves reached
areas under the curve above 70% and statistical signifi-
cance levels below 0.05 for the three instruments used
on admission (NIHSS, Barthel and modified Rankin
scales) (Table 5 and Figure 2).
Discussion
The main conclusion from the results of this study is
that the prognosis of stroke in Spain has changed in re-
cent years. Both survival and functional outcome have
improved as a result of the introduction of a new model
of care [18,32]. This new model, based on stroke units,
thrombolysis, physical therapy and secondary preven-
tion, has been promoted by the stroke strategy of the
Spanish National Health Service in coordination with re-
gional health authorities and healthcare professionals
[8,9].
The in-hospital mortality rate (5.9%) is well below the
10% reported in 2006 in the U.S [32]. Compared to the
30% 1-year mortality rate described in the literature, this
figure has dropped to 18.3% [18,32]. Also striking is the
sequence of disability-scale measurements that shows a
functional recovery process in which good levels of au-
tonomy (0–2 on the modified Rankin scale) increase
from 51% at discharge from hospital to 71% in the survi-
vors at 1 year. These good results after discharge show
that the development of post-stroke rehabilitation and
the inclusion of physical therapy in the Spanish Stroke
Plan improved the prognosis [8,9].
Thrombolytic therapy is a good prognostic factor, as
treated patients were found to have statistically significant
OR above 2 in the Barthel and modified Rankin scales in
Table 2 Changes in level of autonomy and quality of life scales from hospital admission up to 1 year later
Previous Discharge 3 months 12 months
Modified rankin scale N (%) N (%) N (%) N (%)
From 0 to 2 299 (93.7%) 165 (54.6%) 186 (67.1%) 182 (71.1%)
Above 2 20 (6.3%) 137 (45.4%) 91 (32.9%) 68 (28.9%)
Barthel N (%) N (%) N (%)
Independent (100) 91 (28.3%) 130 (40.5%) 132 (41.1%)
Low dependence (91–99) 11 (3.4%) 22 (6.9%) 17 (5.3%)
Moderate dependence (61–90) 93 (29.0%) 55 (17.1%) 50 (15.6%)
Severe dependence (21–60) 57 (17.8) 48 (15.0%) 32 (10.0%)
Total dependence (0–20) 50 (15.6%) 23 (7.2%) 19 (5.9%)
Cumulative deaths 19 (5.9%) 35 (10.9%) 56 (17.4%)
EQ-5D Discharge 3 months 12 months
Utilities mean (SD) 0.57 (0.32) 0.62 (0.30) 0.65 (0.28)
Visual Analogic Scale mean (SD) 45.81 (28.62) 44.15 (31.56) 45.74 (33.36)
Number of responses 274 261 234
EQ-5D dimensions N (%) N (%) N (%)
Mobility No problems 122 (44.2%) 137 (52.5%) 123 (52.1%)
Some problems 100 (36.2%) 98 (37.5%) 100 (42.4%)
Confined to bed 54 (19.6%) 26 (10.0%) 13 (5.5%)
Personal care No problems 137 (49.8%) 156 (59.8%) 155 (67.7%)
Some problems 75 (27.3%) 36 (13.8%) 52 (22.0%)
Unable 63 (22.9%) 69 (26.4%) 29 (12.3%)
Activity No problems 83 (30.1%) 116 (44.4%) 116 (49.2%)
Some problems 122 (44.2%) 44 (16.9%) 84 (35.6%)
Unable 71 (25.7%) 101 (38.7%) 36 (15.3%)
Pain No pain 171 (62.4%) 159 (60.9%) 140 (59.3%)
Moderate pain 94 (34.3%) 88 (33.7%) 86 (36.4%)
Extreme pain 9 (3.3%) 14 (5.4%) 10 (4.2%)
Anxiety Not anxious 153 (55.8%) 131 (50.2%) 134 (56.8%)
Moderately anxious 103 (37.6%) 102 (39.1%) 89 (37.7%)
Extremely anxious 18 (6.6%) 28 (10.7%) 13 (5.5%)
Cumulative losses 0 8 15
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years ago is the time to arrival at hospital, with the median
dropping from 6 hours to 3 hours. Along with stroke unit
care, this explains why a third of patients received thromb-
olysis. Multivariate analysis made it possible to see its asso-
ciation with better prognosis despite the NIHSS variable
acting as a confounding factor. A low NIHSS score gener-
ally corresponds to patients with neurological deficit that is
only slightly disabling, and is one of the exclusion criteria
in summaries of product characteristics to avoid the risk of
bleeding. However, these results and those from a recent
clinical trial have led to a rethink, as it is known that not all
cases with low NIHSS have a good outcome [33].In the analysis of factors influencing prognosis, as in
other studies, the NIH stroke severity scale stands out
[34]. Patients with low admission NIHSS show good
prognosis, OR 3 to 7 times higher according to the out-
come variable. Younger age is associated with a good
prognosis at 1 year on the mRS and for mortality but
not with the BI and the EQ-5D. Men have better prog-
nosis when the outcome is measured with the BI and
the EQ-5D. The EQ-5D results may be due to the fact
that this difference is also found when analysing the
general population [28]. Studies suggest that in general,
the poorer HRQOL reported in older women is mainly
due to a higher prevalence of disability and chronic
Figure 1 Frequency histogram of the level of dependence from admission up to 12 months.
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Visual Analogic Scale the results were near the same in
the three measurements. This lack of sensitivity to
change can be attributed to the limited validity of the
thermometer to identify the preferences of stroke
patients.
The quality of life at 1 year observed in our study is
clearly higher (0.65) than that obtained in other Spanish
studies conducted in 2000 and 2004 in which the aver-
age values were 0.49 and 0.50 respectively [16,36]. In
the comparison of the characteristics of our sample with
both studies we see that age and sex distributions were
similar (mean age 72 years was and 55% of males). How-
ever the percentage of haemorrhages was lower in our
study. As the sample sizes in both studies were small we
need to be cautious to draw conclusions but it seems
plausible that the changes found in terms of improved
time to arrival at hospital, thrombolysis, rehabilitationTable 3 Distribution of variables for level of autonomy at 12
Barthel
100 0-95
Gender (Male) 87 (65.9%) 52 (44.1%)
Age < 75 years 86 (65.2%) 58 (49.2%)
NIHSS on admission > 5 50 (37.9%) 77 (65.3%)
Infarction vs. Haemorrhage 120 (90.9%) 106 (89.8%)
Thrombolysis 42 (31.8%) 40 (33.9%)
Arrival time < 3 h 66 (51.2%) 59 (51.8%)
Atrial Fibrillation 52 (39.4%) 64 (54.2%)
NIHSS: National Institute of Health Stroke Scale.and stroke units have had a direct bearing on the im-
provement in HRQOL. Despite these changes, the gen-
eral population over age 65 still has an HRQOL 11%
higher than the sample of patients with stroke. This dif-
ference, which can be interpreted as a clinically signifi-
cant difference as it exceeds the range of 0.074 to 0.080
cited in the literature [37,38], reminds us that much
more can still be done to minimise the functional im-
pact of stroke. What is important is that many patients
who suffer stroke have a very low HRQOL as a result of
the loss of functional autonomy, and responding to this
problem continues to be a challenge for public health
[37]. The effect size of the intervention from discharge
to the year is small according to the Cohen criteria [30].
However it is an important element to measure because
it allows monitoring of the impact of tertiary stroke pre-
vention. As the sample included some aphasic patients
who were unable to communicate, the use of proxiesmonths according to clinical characteristics
Modified rankin scale
p 0-2 3-5 p
0.001 107 (58.8%) 32 (47.1%) NS
0.015 26 (38.2%) 118 (64.8%) 0.015
<0.001 74 (40.7%) 53 (77.9%) <0.001
NS 165 (90.7%) 61 (89.7%) NS
NS 57 (31.3%) 25 (36.8%) NS
NS 90 (50.6%) 35 (53.8%) NS
0.022 76 (41.8%) 40 (58.8%) 0.022
Table 4 Results from logistic regressions relating the characteristics of stroke patients and the 1-year outcome
Barthel 100 mRS 0-2 EQ-5D 1 Barthel <60 Death
p OR p OR p OR p OR p OR
Haemorrhage NS NS 0.046 0.261 NS NS
Atrial Fibrillation NS NS NS NS NS
Age over 75 NS 0.001 0.335 NS NS 0.000 6.196
NIHSS (0–5) 0.000 3.882 0.000 6.985 0.010 2.769 0.000 0.234 0.000 0.201
Male 0.007 2.137 NS 0.005 2.723 NS NS
Thrombolysis 0.047 2.173 0.036 2.540 NS NS 0.006 0.307
Arrival time NS NS NS NS NS
mRS: modified Rankin Scale. OR: Odds ratio. NIHSS: National Institute of Health Stroke Scale.
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including proxy responses outweigh the loss of informa-
tion that occurs when those patients are excluded, be-
cause the most impaired group is a key component of
the prevalent stroke population [28].
The gender analyses can be interpreted as stroke units
having reduced gender inequalities in care for stroke pa-
tients. We did not find the association between being fe-
male and higher mortality rates which has been reported
by other studies [39] and there is no gender distinction
in access to thrombolysis. The differences found in qual-
ity of life have also been described in the general popula-
tion [30,35].
The age-standardised mortality rates for stroke have
fallen worldwide over the past two decades [13]. How-
ever, despite this improvement in the epidemiological
profile, we must not forget that stroke still represents
one of the leading causes of death and disability. The
absolute number of strokes, the prevalence of associ-
ated disability, the related deaths and the total global
burden are large and have not come down [40,41].
Challenges remain, such as raising the percentage of pa-
tients receiving thrombolysis and controlling risk fac-
tors like hypertension or atrial fibrillation. The
proportion of patients receiving thrombolytic treatment
is very high (33%) but can still be improved. Identifica-
tion of thrombolysis as a factor associated with good
prognosis provides an incentive to maintain the goal of
improving public awareness of stroke as a medicalTable 5 Area under the curve and significance values for the
instruments applied on admission with outcome at 1 year
1-year outcome Barthel =100 Rankin 0-2
Instrument on admission AUC p AUC p
NIHSS 0.677 0.000 0.717 0.000
Barthel 0.856 0.000
modified Rankin 0.779 0.000
AUC: area under the curve. p: statistical significance value.emergency. Additional options for this are the increased
time window for thrombolysis and generalisation of
endovascular treatment.
The three instruments applied on admission (NIHSS,
Barthel and modified Rankin scales) showed good dis-
criminating characteristics with measurements of good
prognosis. In all cases the AUC exceeded 70% and tests
of significance were statistically significant. Their use
may make it possible to predict the functional outcome
and thus help patients and families to prepare their re-
sponse to the new social needs.
Quality indicators are currently collected in different
European countries to monitor in the real world the
quality of care received by stroke patients [42]. However,
the huge variety in measuring the performance of stroke
care hampers comparisons [43]. In the same line, our re-
sults describe how successful has been the implementa-
tion of strategies found effective in clinical trials when
applied to Spanish hospitals.
Given that we did not include patients hospitalised in
departments without stroke units, these results are not
representative of all the Spanish stroke population.
Thus, as a limitation we notice that these results are
valid only for the percentage of stroke patients that are
admitted into a stroke unit [44]. This figure has in-
creased during the last years allowing the patients to re-
ceive a specific and proactive treatment. However, this
study shows that decision-makers need to follow the
recommendations from the Spanish Stroke Plan toROC curves measuring the discriminatory capacity of the
EQ-5D Barthel <60 Death 1 year
AUC p AUC p AUC p
0.670 0.000 0.671 0.000 0.765 0.000
0.718 0.000 0.835 0.000
0.737 0.000 0.598 0.028 0.811 0.039
Figure 2 ROC curves measuring the discriminatory capacity of
the modified Rankin, NIHSS and Barthel instruments applied on
admission with the prognosis of 1-year mortality. NIHSS:
National Institute of Health Stroke Scale.
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sion of the model to the majority of the more than
100,000 strokes that occur annually in Spain [45].
Expanding the coverage can be achieved by increasing
the number of stroke units or through the use of tele-
medicine systems which allow the new techniques to be
implemented even in rural areas where the population
has poor access to tertiary hospitals such as those in-
cluded in this study [46].
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